FindTrial
Sign In

Vancomycin (POC)

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Brigham and Women's Hospital, University of Maryland, Baltimore

Conditions

Clostridioides DifficileClostridioides Difficile InfectionInflammatory Bowel Disease (IBD)Moderate Clostridium Difficile InfectionVancomycin Resistance Enterococcus Faecium

Phase 2

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
CompletedNCT01232595
Novartis PharmaceuticalsModerate Clostridium Difficile Infection
Start: 2010-10-31End: 2013-07-31Updated: 2020-12-19
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
WithdrawnNCT07221708
University of Maryland, BaltimoreClostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Start: 2027-01-01End: 2027-12-31Updated: 2026-07-29

Phase 4

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
Not yet recruitingNCT06794944
Brigham and Women's HospitalClostridioides Difficile Infection, Inflammatory Bowel Disease (IBD)
Start: 2026-09-30End: 2031-09-30Target: 60Updated: 2025-11-03

Related Papers

Multicenter, Randomized Clinical Trial To Compare the Safety and Efficacy of LFF571 and Vancomycin for Clostridium difficile Infections
Antimicrobial Agents and Chemotherapy2014-12-23100 citations
Pharmacokinetics of LFF571 and Vancomycin in Patients with Moderate Clostridium difficile Infections
Antimicrobial Agents and Chemotherapy2014-12-2335 citations